AD study in patients with genotype fails, Pfizer says

Pfizer Inc has announced the failure of the first of four studies of a prospective antibody treatment for patients with mild-to-moderate Alzheimer’s disease who carry the ApoE4 genotype. The other three studies are still ongoing.